Aardvark Therapeutics, Inc. (AARD) stock

AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30

$1.33−0.19 (-12.50%)

Close on Nov 13, 2026Market cap $29.11MP/E –Yield –

Aardvark Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Aardvark Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$75.93M. For fiscal 2025 it was -$62.69M.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$62.69M	–
FY2024	Dec 31, 2024	-$22.77M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$19.71M	–
Q2 FY2026	Jun 30, 2026	-$15.07M	–
Q1 FY2026	Mar 31, 2026	-$22.45M	–
Q4 FY2025	Dec 31, 2025	-$18.69M	–
Q3 FY2025	Sep 30, 2025	-$17.69M	–
Q2 FY2025	Jun 30, 2025	-$15.84M	–
Q1 FY2025	Mar 31, 2025	-$10.47M	–
Q4 FY2024	Dec 31, 2024	-$9.44M	–
Q3 FY2024	Sep 30, 2024	-$5.08M	–
Q2 FY2024	Jun 30, 2024	-$6.08M	–
Q1 FY2024	Mar 31, 2024	-$2.17M	–

Parsed from the XBRL in Aardvark Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AARD.

Advertisement
300 × 250

See a number that looks wrong?